AB Science plummets on second CHMP rejection for canine anticancer
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's committee for medicinal products for human use ( CHMP) has turned down AB Science's application to market pancreatic cancer drug Masiviera (masitinib) in Europe.
You may also be interested in...
Helsinn And AB Science Persevere In EU Despite CHMP Setback
Helsinn and AB Science plan to conduct additional studies with their products the CHMP turned down this month, in an effort to secure eventual EU approval in the rejected indications. A third company, XBiotech, hasn’t ruled out similar action. New MAAs would be required.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.